Bolt Biotherapeutics, a biotechnology company focused on unleashing the power of the immune system to achieve anti-tumor immunity in patients, today announced the completion of the $54M Series B funding led by Pivotal BioVenture Partners with additional participation from Nan Fung Life Sciences. Existing investors Novo Holdings and Vivo Capital also participated in the financing process. The funds will be used to bring the company’s lead BoltbodyTM Immune-Stimulating Antibody Conjugate (ISAC) into the clinic as well as to build the company’s pipeline and further develop its technology platform.
“We have made significant progress with our BoltbodyTM ISAC platform, which leverages the ability of toll-like receptor agonists to convert cold tumors to immunologically hot tumors following systemic administration. We are well positioned to bring this new technology into clinical development and look forward to sharing more about our lead program, pipeline and platform in the months ahead,” said Peter Moldt, Ph.D. D. D. , of Novo Ventures and Chairman of the Board of Bolt Biotherapeutics “We are pleased that this group of world-class biotech investors has chosen to join us in this important mission of developing a unique class of cancer immunotherapy. “That’s right.
“The rapid development of Bolt’s promising targeted therapeutic platform has been very impressive,” said Ash Khanna, Ph. D. D. Venture Partner of Pivotal BioVenture Partners “Bolt’s proprietary ISAC technology differs from other immuno-oncology approaches as evidenced by the strength of pre-clinical safety and efficacy data, including long-lasting systemic anti-tumor immunity, and I look forward to working with experienced teams and investors to advance company programs to the clinic. “That’s right.
About Bolt Biotherapy
Bolt Biotherapy, Inc. The San Francisco Bay Area is a private biotechnology company developing BoltbodyTM Immune-stimulating Antibody Conjugates (ISAC), a new cancer therapy class. These systemically administered, tumor-targeted BoltbodyTM therapists release the immune system to induce anti-tumor immunity The company is led by a team with extensive drug discovery and development experience in oncology. Bolt has been founded by Dr. Ed Engleman, Professor of Pathology and Medicine, Stanford Medicine, and its platform is based on technology exclusively licensed by Stanford University. Novo Holdings and Vivo Capital led the $17M Series A round For more information on Bolt Biotherapeutics, please visit www. Boltbio’s Come on,
Pivotal BioVenture Partners
Pivotal BioVenture Partners is a $300 million life science venture capital fund that invests in privately owned North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. The Fund invests at all stages in the evolution of a company, from the creation of a company to the mid-and late-stage clinical development. The team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their business.
About New Holdings
Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-leading life science investor focused on creating long-term value. Novo Holdings is a holding company of the Novo Group which manages the investment assets of the Novo Nordisk Foundation. The company invests in life science companies at all stages of development and in a wide portfolio of equity and fixed income securities.
About the Capital of Life
Vivo Capital is a healthcare-based investment firm founded in 1996 with over $3 billion under management.
Vivo has a unique multi-pronged strategy to identify and work with companies with promising therapeutic products at all stages in the U. Oh, S And revenue-level companies in Greater China Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the fields of biopharmaceuticals, specialty pharmaceuticals and medical devices. Vivo Capital is based in Palo Alto, California, Beijing, Shanghai and Taipei.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Bolt%20Biotherapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
